In a deal that both partners cited as "transformative" for their companies and for the field of immunotherapeutics, Celgene Corp. enlisted Juno Therapeutics Inc. as a partner in a broad, global collaboration to leverage T-cell therapies and develop treatments targeting cancer and autoimmune diseases.